POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study

Autor: Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Prince, H. Miles, Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Jethava, Yogesh, Gabayan, Afshin E., Stevens, Don A., Nooka, Ajay K., Raje, Noopur, Iida, Shinsuke, Leip, Eric, Conte, Umberto, Czibere, Akos, Viqueira, Andrea, Lesokhin, Alexander M.
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S225-S225
Databáze: ScienceDirect
Externí odkaz: